Home

Thursday, May 24, 2018 - 13:52
The ingredients and science behind growth factor-based topicals.By Inga HansenGrowth factor-BASED serums and creams have become ubiquitous in topical antiaging skin care. But what these different products contain can vary widely. Some products contain actual growth factors—either animal- or plant-derived—and others use so-called “signaling” ingredients, typically peptides that trigger the cells in a manner similar to naturally occurring growth factors. In all cases, the goal is to combat the changes that occur in aging skin
https://www.medestheticsmag.com/restoring-growth
Thursday, May 24, 2018 - 13:52
The ingredients and science behind growth factor-based topicals.By Inga HansenGrowth factor-BASED serums and creams have become ubiquitous in topical antiaging skin care. But what these different products contain can vary widely. Some products contain actual growth factors—either animal- or plant-derived—and others use so-called “signaling” ingredients, typically peptides that trigger the cells in a manner similar to naturally occurring growth factors. In all cases, the goal is to combat the changes that occur in aging skin
https://www.medestheticsmag.com/restoring-growth
Thursday, May 24, 2018 - 13:36
The U.S. Food and Drug Administration (FDA) has approved the hyaluronic acid (HA) dermal filler Restylane Lyft (Nestlé Skin Health) for the correction of age-related volume loss in the back of the hands for patients over the age of 21. It is the first HA injectable gel to be FDA-approved for restoring fullness to the back of the hands.
https://www.medestheticsmag.com/restylane-lyft-approved-hands

Advertisement - Box 1

Advertisement - Box 2

Thursday, May 24, 2018 - 13:36
The U.S. Food and Drug Administration (FDA) has approved the hyaluronic acid (HA) dermal filler Restylane Lyft (Nestlé Skin Health) for the correction of age-related volume loss in the back of the hands for patients over the age of 21. It is the first HA injectable gel to be FDA-approved for restoring fullness to the back of the hands.
https://www.medestheticsmag.com/restylane-lyft-approved-hands
Thursday, May 24, 2018 - 13:32
Revance Therapeutics has established four new positions at the company as it prepares for the launch and commercialization of its daxibotulinumtoxinA injectable (RT002) for the treatment of glabellar lines.
https://www.medestheticsmag.com/revance-gears-launch-rt002-neurotoxin
Thursday, May 24, 2018 - 13:32
Revance Therapeutics has established four new positions at the company as it prepares for the launch and commercialization of its daxibotulinumtoxinA injectable (RT002) for the treatment of glabellar lines.
https://www.medestheticsmag.com/revance-gears-launch-rt002-neurotoxin

Advertisement - Box 3

Advertisement - Box 4

Friday, June 8, 2012 - 14:55
Deck:  The FDA clears Cellulaze, the first minimally invasive procedure specifically indicated for the treatment of cellulite. Main Image:  Cellulite treatments are a multibillion-dollar industry in the United States alone. More than 80% of women are afflicted with the cottage cheese appearance of cellulite, and they have been rubbing on lotions, sweating through wraps and enduring deep kneading sessions for years. Results of these treatments have often been...
http://medestheticsmag.com/cellulite-game-changer
Tuesday, June 5, 2012 - 16:24
Learn how to create the Jessie and Roxy Clarvoyance looks with these stepss from Scruples Technicals:Jessie: ColourNatural level: 7Base colour: TRUE INTERGRITY Opalescent Colour Creme        Ash (1A)Prelighten: POWER BLONDE Lightening Powder (on triangles) Procedure:  Jessie: See first image for Steps 1 & 2. Roxy: See second image for Steps: 1, 2 & 3. jessie_steps.jpg...
http://www.thecoloristmag.com/scruples-technicals-clarvoyance
Friday, February 3, 2012 - 12:08
Deck:  Galderma reports positive top-line results from its Phase 2b trial of a novel medication to treat the redness of rosacea. Main Image:  In late October 2011, Galderma Pharma S.A. (www.galderma.com) announced top-line results from its Phase 2b trial of CD07805/47 gel 0.5%, the company’s proprietary brimonidine tartrate formulation. The results confirm the gel’s potential to become a viable topical treatment option for the persistent facial redness of rosacea....
http://www.medestheticsmagazine.com/battling-red-menace

Pages

Advertisement - Box 5

Advertisement - Box 6